Chemomab Therapeutics (CMMB)

Executive Summary

Chemomab Therapeutics (NASDAQ: CMMB) is a clinical-stage biotechnology company focusing on the development of CM-101, a monoclonal antibody targeting CCL24, to treat fibrotic and inflammatory diseases with high unmet need. The company is advancing Phase 2 trials for systemic sclerosis, primary sclerosing cholangitis, and metabolic dysfunction-associated steatohepatitis (MASH). By neutralizing CCL24, CM-101 aims to directly address the pathological processes underlying these conditions. Chemomab is publicly traded and funded through market financing and collaborations, supporting its clinical programs and research operations.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Top-Line Results for Systemic Sclerosis60% success
• Q4 2026Phase 2 Interim Data for Primary Sclerosing Cholangitis50% success
• H1 2027Phase 2 Initiation for MASH80% success